Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-137032

Published: 2020

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

Pierre Bories, MD, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2018-99-117219

Published: 2018

Journal Articles

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Emilie Berard, MD, Noemie Gadaud, Audrey Sarry, Francoise Huguet, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2018) 132 (Supplement 1): 2802.

https://doi.org/10.1182/blood-2018-99-113109

Published: 2018

Journal Articles

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Edmond Chiche, Sarah Bonnet, Sarah Bertoli, MD PhD, Andrew T Kuykendall, MD, Lauris Gastaud, Pascal Boulay, Veronique De Mas, Eric Delabesse, MD PhD, Alice Marceau-Renaut, Claude Preudhomme, Anne Murati, David A Sallman, MD, S. Dominique Raynaud, MD, Christian Recher, MD PhD, Norbert Vey, MD PhD, Thomas Cluzeau, MD PhD

Blood (2018) 132 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2018-99-114428

Published: 2018

Journal Articles

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Pierre Bories, MD, Naïs Prade, Bastien Cabarrou, Stéphanie Lagarde, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 1467.

https://doi.org/10.1182/blood-2018-99-117336

Published: 2018

Journal Articles

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Francoise Huguet, MD, Muriel Picard, MD, Francois Vergez, DVM, PhD, Eric Delabesse, MD PhD, Audrey Sarry, Emilie Berard, MD, Christian Recher, MD PhD

Blood (2017) 130 (Supplement 1): 3903.

https://doi.org/10.1182/blood.V130.Suppl_1.3903.3903

Published: 2017

Journal Articles

B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL

Blood (2017) 130 (Supplement 1): 2572.

https://doi.org/10.1182/blood.V130.Suppl_1.2572.2572

Published: 2017

Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Blood (2017) 130 (Supplement 1): 1722.

https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722

Published: 2017

Journal Articles

Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML

Francois Vergez, DVM, PhD, Sarah Bertoli, MD PhD, Marina Bousquet, PhD, Marie-Laure Nicolau-Travers, Michael Peres, PharmD, Estelle Saland, Françoise Huguet, MD, Isabelle Luquet, MD, Veronique Mansat-de Mas, PharmD, PhD, Cecile Demur, MD, Eric Delabesse, MD PhD, Gwenn Danet-Desnoyers, PhD, Jean-Emmanuel Sarry, PhD, Christian Récher, MDPhD

Blood (2015) 126 (23): 90.

https://doi.org/10.1182/blood.V126.23.90.90

Published: 2015

Journal Articles

T315I-Mutated BCR-ABL Induces a Distinct and Specific Molecular Signature With High Expression Of Zinc Finger (ZNF) Transcription Factors

Christophe Desterke, PhD, Djamel Aggoune, Marie Laure Bonnet, Nais Prade, Jean-Claude Chomel, PharmD, PhD, Eric Delabesse, MD, PhD, Ali G Turhan, MD, PhD

Blood (2013) 122 (21): 4899.

https://doi.org/10.1182/blood.V122.21.4899.4899

Published: 2013

Journal Articles

Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias

Thomas Prebet, MD, PhD, Sarah Bertoli, Eric Delabesse, MD, PhD, Marie-Joelle Mozziconacci, MD, Anne Etienne, MD, Christian Recher, MD PhD, Françoise Huguet, Norbert Vey, MD

Blood (2013) 122 (21): 2681.

https://doi.org/10.1182/blood.V122.21.2681.2681

Published: 2013

Journal Articles

Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia

Fabienne de Toni, PhD, Robin L. Perry, MD, Estelle Saland, Mayumi Sugita, MD, Marion David, PhD, François Vergez, VMD, Eric Delabesse, MD, PhD, Véronique De Mas Mansat, PharmD PhD, Cécile Demur, MD, Jason Iacovoni, PhD, Stéphane Manenti, PhD, Gwenn Danet-Desnoyers, Christian Recher, MD PhD, Martin Carroll, MD, Jean-Emmanuel Sarry, PhD

Blood (2013) 122 (21): 1651.

https://doi.org/10.1182/blood.V122.21.1651.1651

Published: 2013

Journal Articles

Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.

Loic Ysebaert, MD PhD, Stephanie Struski, Nais Prade, Romain Guieze, MD, Guy Laurent, MD PHD, Eric Delabesse, MD, PhD

Blood (2012) 120 (21): 2879.

https://doi.org/10.1182/blood.V120.21.2879.2879

Published: 2012

Journal Articles

What Is New? An Update of the MLL Recombinome Including the Three Novel Partner Genes ABI2, PDS5A, and TOP3A

Claus Meyer, PhD, Mariana Emerenciano, PhD, Eva A Coenen, MD, Eric Delabesse, MD, PhD, Charles Herbaux, MD, Julia Hofmann, Marry M. van den Heuvel-Eibrink, MD, PhD, C. Michel Zwaan, MD, PhD, Theo Dingermann, PhD, Tae Sung Park, MD, PhD, Thomas Klingebiel, MD, Rolf Marschalek, PhD

Blood (2011) 118 (21): 1351.

https://doi.org/10.1182/blood.V118.21.1351.1351

Published: 2011

Journal Articles

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Benedicte Deau, MD, Mathias Montveneur, MStud, Valérie Coiteux, MD, Aline Renneville, MD, Francoise Rigal-Huguet, MD, Eric Delabesse, MD, PhD, Michel Tulliez, MD, Dominique Bories, MD, PhD, Aude Charbonnier, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Thibault Legay, MD, Eric Lippert, PhD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Jean-Michel Cayuela, PhD, Shanti Amé, MD, Marie-Pierre Gaub, MD, Martine Gardembas, MD, Odile Blanchet, MD, Bruno Audhuy, MD, Agnès Buzyn, MD, PhD, Elisabeth Mac Intyre, MD, PhD, Anna-Lisa Andreoli, MD, Oumedaly Reman, Nathalie Contentin, MD, Christian Bastard, MD, Jean-Christophe Ianotto, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Said Brahimi, MD, Viviane Dubruille, Jean-Francois Brantus, MD, Mohamad Sobh, Pharm., M., Stephane Morisset, Stat., Claude Preudhomme, MD, PhD, Sandrine Hayette, PhD, Franck E Nicolini, MD, PhD

Blood (2010) 116 (21): 3378.

https://doi.org/10.1182/blood.V116.21.3378.3378

Published: 2010

Journal Articles

Prediction of Relapse Risk by Day 100 BCR-ABL Quantification after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia.

Marie T. Rubio, MD, PhD, Vahid Asnafi, MD, Eric Delabesse, MD, PhD, Gandhi Damaj, MD, Nathalie Dhedin, MD, Bruno R. Varet, MD, Agnes Buzyn, MD, PhD, Elizabeth A. Macintyre, MD, PhD

Blood (2005) 106 (11): 2020.

https://doi.org/10.1182/blood.V106.11.2020.2020

Published: 2005

Journal Articles

Transcriptional Activation of the Cardiac Homeobox Gene CSX1/NKX2-5 in a B-Cell Chronic Lymphoproliferative Disorder.

Xinying Su, MD, Maryvonne Busson, Eric Delabesse, MD, PhD, Zahia Azgui, MD, Roland Berger, MD, PhD, Hélène Merle-Beral, MD, PhD, Olivier A. Bernard, PhD, Florence Nguyen-Khac, MD, PhD

Blood (2004) 104 (11): 4269.

https://doi.org/10.1182/blood.V104.11.4269.4269

Published: 2004

NARROW

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML

T315I-Mutated BCR-ABL Induces a Distinct and Specific Molecular Signature With High Expression Of Zinc Finger (ZNF) Transcription Factors

Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias

Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia

Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.

What Is New? An Update of the MLL Recombinome Including the Three Novel Partner Genes ABI2, PDS5A, and TOP3A

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Prediction of Relapse Risk by Day 100 BCR-ABL Quantification after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia.

Transcriptional Activation of the Cardiac Homeobox Gene CSX1/NKX2-5 in a B-Cell Chronic Lymphoproliferative Disorder.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only